The contract is the third one that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded Xoma to develop botulism antitoxins, the company said in a Sep 9 statement. In 2005 Xoma was among the first companies to receive a contract through Project BioShield, according to a previous report. Xoma reported that its NIAID contracts cover the development of human monoclonal antibody products targeting the three most toxic serotypes of botulinum toxin, types A, B,and E. The company also said these human antibody products are expected to be safer than existing animal-derived antibodies, which it said cause serious immune reactions in some patients and vary unpredictably in their efficacy. See also: Sep 11, 2008 (CIDRAP News) – Xoma Ltd., a Berkeley, Calif., pharmaceutical company, recently announced that it received a $65 million multiyear federal contract to fund work on botulinum antitoxins, one of which it hopes to put through safety and efficacy tests starting in 2009. Clostridium botulinum, which produces botulinum toxin, a nerve poison, is among the category A agents that experts say bioterrorists would most likely try to use. However, most botulism cases are caused by tainted food or contaminated wounds. Sep 9 Xoma press release Steven Engle, Xoma’s chairman and chief executive officer, said in the statement that the contract shows the US government’s support of novel therapies that address natural, accidental, or intentional infections from pathogens and their toxins. “Since initiating its biodefense program in 2005, Xoma has used its innovative antibody technology to develop better and safe solutions,” he said. “We plan to continue working with the government’s biodefense development efforts toward future stockpiling initiatives.” Xoma said if studies show that the company’s first botulism antitoxin candidate is safe and effective and government funding continues, it would file the paperwork needed to produce the treatment for the Strategic National Stockpile. The new NIAID contract will cover the next 6 years of botulism antitoxin development, the company said. May 10, 2005, CIDRAP News story “NIAID awards first Project BioShield grants”
The report states a source close to the situation expects Jones to sign a multi-year deal paying him more than $20 million per year with $50 million to $60 million guaranteed. Jones, 30, recorded a league-leading 1,677 receiving yards in 2018-19. He also caught eight touchdowns in a down year for his team. Related News Julio Jones could have a big-time contract on the way.The Falcons receiver is reportedly negotiating a deal which would make him the NFL’s highest-paid wideout, according to Bleacher Report. Adam ‘Pacman’ Jones agrees to plea deal including jail time, alcohol probation Atlanta posted a 7-9 record and finished second in the NFC South last season, despite a horrendous start. Jones is the Falcons’ most dangerous weapon. While he is not scheduled to become an unrestricted free agent until 2021, securing him long-term could prove to be an important move for Atlanta.
KILLYBEGS soccer star Seamus Coleman is celebrating today after being named Everton’s young player of the year.The 22-year-old Donegal man will make an incredible 40th appearance of the season when his side entertain Chelsea at Goodison Park on Sunday.He has started 30 of those games – and scored six goals for his club. And last night in Liverpool, Seamus picked up two gongs – young player of the year – and shareholders’ player of the year.Manager David Moyes said “Seamus did tremendously well at Blackpool last season and he’s given us something fresh and new this year.“He’s been great and, with what we’ve seen, we hope he’ll be able to step up again.”The former St Catherine’s and Sligo Rovers player won’t end his season against Chelsea however. He is expected to feature for Ireland when they play the North in the Carling Nations Cup next Tuesday – and Scotland on Sunday week.Said Seamus after the ceremony: “I’m trying to pick up different things but I don’t want to lose that natural ability.“I just like being able to get it and go. It’s done me well so far, so hopefully that can continue to be the case. I haven’t had a whole load of coaching. I just go for it. I want to get past my full-back. If I don’t do it the first time, I’ll keep trying.“It’s still there a little bit, that feeling that it’s all a bit surreal. I’ve said to myself that I’ve got to get rid of that because you can’t always think that way. At the same time, I don’t want to get used to it. I still want to have that little feeling of being in awe because you can never take your place for granted.”COLEMAN NAMED EVERTON YOUNG PLAYER OF THE YEAR was last modified: May 20th, 2011 by gregShare this:Click to share on Facebook (Opens in new window)Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Reddit (Opens in new window)Click to share on Pocket (Opens in new window)Click to share on Telegram (Opens in new window)Click to share on WhatsApp (Opens in new window)Click to share on Skype (Opens in new window)Click to print (Opens in new window) Tags:evertonKillybegsseamus coleman